Programmable Bio · Hyderabad, India

Your model designed it.
Our autonomous lab tests it.

We operate a compact, fully autonomous R&D lab in Hyderabad. It is running now. We are opening selected programs to academic and industry teams while raising capital to expand its instruments, assays, and throughput.

Status: operational R&D cell
Location: Hyderabad, India
Next: scale capacity and access

Operational today. The Hyderabad lab executes automated wet-lab workflows end to end. Customer access begins through a reviewed expression of interest; a self-serve catalog and API follow as each assay is standardized.

Biology is becoming programmable

Models can now generate proteins, sequences, constructs, and experimental plans faster than laboratories can test them. The scarce resource is no longer a plausible design. It is trustworthy physical evidence.

Programmable biology needs an execution layer: software translates intent into lab operations, automation runs the experiment, and structured results flow back into the model. Our Hyderabad lab is the first compact implementation of that loop.

Design → execute → measure → learn. The product is not a robot or a report. It is a repeatable experimental loop.

From computational design to experimental evidence

Design
Your candidates
Review
Feasibility + quote
Execute
Hyderabad lab
Return
Data + provenance
Learn
Next design cycle

Initial programs are reviewed with our team so we only accept work the current cell can execute reliably. Standardized workflows will move into transparent, self-serve ordering as the public catalog expands.

See the detailed operating model →

Start with a working cell. Scale into a network.

Automation already running

The core execution loop is operational in our Hyderabad R&D setup. Funding expands breadth and throughput rather than financing a first demonstration.

Price parity as a baseline

Our launch targets match published cloud-lab prices. The India cost base is intended to preserve margin while keeping experiments accessible.

Model-ready output

Each standardized assay is designed to return structured results, raw files, QC context, and execution provenance.

Clinical context is proposed

We are pursuing, but have not signed, an Apollo partnership for consented clinical and biobank access. It is an expansion path, not a current asset.

One lab, two access models

Academic R&D

Small, grant-sized experimental batches for teams whose computational output is growing faster than their bench capacity.

Industry R&D

Pilot programs now, followed by reserved capacity and API-driven design–build–test–learn loops as the fleet scales.

From design to data

The lab is operational. Access is deliberately reviewed while the catalog is small; standardized assays move to self-serve ordering as capacity expands.

Current access: selected academic and industry pilots through an expression of interest. Planned access: instant compatibility checks, published checkout, and an API for standardized workflows.

1

Submit an expression of interest

Tell us the assay class, sample type, approximate batch size, and desired turnaround. Do not send confidential sequences or patient data through the public form.

2

Feasibility review and quote

We map the request to the current Hyderabad cell, identify any method-development work, and return scope, price, inputs, and an estimated completion window.

3

Secure technical intake

Accepted programs receive a secure channel for sequences, protocols, material-transfer details, and acceptance criteria.

4

Autonomous execution

LabOS schedules the workflow, drives the connected instruments, monitors controls, and records the parameters and materials used in the run.

5

Structured results

Customers receive parsed results, raw instrument files, QC context, and an execution record suitable for analysis or the next model-training cycle.

Pricing targets benchmarked to the market

Illustrative planning assumptions. These are target launch prices and service levels, not a claim of current catalog availability or historical performance. Final quotes depend on method fit, batch size, materials, and shipping.

RNA synthesis + qPCR

$99 / sample
Target: up to 12 business days

Automated synthesis, purification, and quantitative readout for standardized inputs.

Cell-free expression + A280

$149 / sample
Target: up to 11 days

Expression, affinity purification, yield quantification, controls, and raw data.

E. coli expression + A280

$199 / sample
Target: up to 3 weeks

Transformation through expression, purification, yield measurement, and QC.

Thermal-shift characterization

$159 / sample
Target: up to 12 days

Expression, purification, and standardized thermal unfolding measurements.

Plate-reader assay onboarding

$399 / assay
Target: 3–4 weeks

One method-development iteration and qualification run for a compatible assay.

SPR target onboarding

$1,399 / target
Target: up to 4 weeks

Target qualification for subsequent binder-kinetics programs.

Benchmark checked 31 July 2026 against the public Ginkgo Cloud Lab protocol catalog. Programmable Bio intends to match these published prices at launch; this comparison should be rechecked before publication.

What every standardized run should return